Why the study?
Does ticagrelor improve cardiovascular outcomes compared to conventional P2Y12 inhibitors in patients with acute coronary syndrome?
Population
Patients with acute coronary syndrome
Comparison
Ticagrelor vs Conventional P2Y12 receptor inhibitors
Design
Review
Authors
Loading...
May guide ticagrelor selection in ACS; leaves open need for updated head-to-head RCTs.
Does ticagrelor improve cardiovascular outcomes compared to conventional P2Y12 inhibitors in patients with acute coronary syndrome?
This review highlights the pharmacological properties and clinical utility of ticagrelor compared to conventional P2Y12 inhibitors for preventing recurrent ischemic events in acute coronary syndrome.
Davis et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: